Evidence map›Paper›PMID 40844672›Full record

ReviewPurinergic signalling2025

The P2X7 receptor in leukemia: pathological mechanisms and therapeutic potential.

Yanwen Xue, Xiaoxiang Peng, Meng Yan, Yanan Du, Yahui Cao, Ronglan Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanwen Xue *School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Xiaoxiang Peng *School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Meng YanSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Yanan DuSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Yahui CaoSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Ronglan ZhaoSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China. ronglanzhao@sdsmu.edu.cn.ORCID http://orcid.org/0000-0002-4302-2563

Funding

National Natural Science Foundation of China 81770915 and 81301737Natural Science Foundation of Shandong Province ZR2023MH307andZR2021MH306
6 · The paper itself

Abstract

The P2X7 receptor is a trimeric ion channel purinergic receptor. It plays a crucial part in the pathophysiology of cancers and a variety of inflammatory diseases and is widely expressed in different cell types. Leukemia represents a type of malignant clonal disorder that impacts the hematopoietic stem cells. Chemotherapy is one of the main treatment methods for leukemia, but there are also many side effects. In recent years, targeted therapy is a new treatment method. Research has shown that the progression and occurrence of leukemia is significantly related to the P2X7 receptor. The P2X7 receptor is also involved in the migration and invasion of leukemia cells. Furthermore, the polymorphism of the P2X7 receptor gene also takes on a significant function in the occurrence, development and clinical course of leukemia patients. The P2X7 receptor inhibitors have been found to work better in combination with existing therapeutics. Therefore, the P2X7 receptor may serve as a potential therapeutic target.

Indexed as

LeukemiaReceptors, Purinergic P2X7AnimalsDisease ProgressionHumansMolecular Targeted TherapyPolymorphism, Single NucleotidePurinergic P2X Receptor AntagonistsP2RX7 protein, humanPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7ATPImmunoregulationLeukemiaP2X7 gene polymorphismP2X7 receptorP2X7 receptor antagonist

Identifiers

PMID40844672
PMCPMC12722618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.